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The aggressiveness of prostate cancer (PCa) varies widely: some tumors progress to invasive, potentially life-
threatening disease, whereas others stay latent for the remainder of an individual’s lifetime. The mechanisms resulting
in this variability are not yet understood, but they are likely to involve both genetic and environmental influences.
To investigate genetic factors, we conducted a genomewide linkage analysis of 513 brothers with PCa, using the
Gleason score, which reflects tumor histology, as a quantitative measure of PCa aggressiveness. To our knowledge,
this is the first time that a measure of PCa aggressiveness has been directly investigated as a quantitative trait in a
genomewide scan. We employed a generalized multipoint Haseman-Elston linkage-analysis approach that regresses
the mean-corrected cross product between the brothers’ Gleason scores on the estimated proportion of alleles shared
by brothers identical by descent at each marker location. Our results suggest that candidate regions on chromosomes
5q, 7q, and 19q give evidence for linkage to PCa-aggressiveness genes. In particular, the strongest signals detected
in these regions were at the following markers (with corresponding P values): for chromosome 5q31-33, between
markers D5S1480 and D5S820 ( ); for chromosome 7q32, between markers D7S3061 and D7S1804P = .0002
( ); and, for chromosome 19q12, at D19S433 ( ). This indicates that one or more of these candidateP = .0007 P = .0004
regions may contain genes that influence the progression of PCa from latent to invasive disease. Identification of
such genes would be extremely valuable for elucidation of the mechanism underlying PCa progression and for
determination of treatment in men in whom this disease has been diagnosed.
Introduction
Prostate cancer is the most common neoplasm among
men in the United States: in the year 2000, ∼180,400
men in the United States will receive a diagnosis of pros-
tate cancer (PCa [MIM 176807]), a disease accounting
for ∼31,900 deaths annually (Greenlee et al. 2000). This
disease will be diagnosed in ∼15% of men in the United
States, and the results of autopsy studies suggest that
30% of men of age 145 years may have prostate lesions
that are histologically identifiable as PCa (Dhom 1983;
Kosary et al. 1995). While a good number of these le-
sions will remain latent for a man’s lifetime, little is
currently known about what makes some PCa biologi-
cally aggressive and more likely to progress to metastatic
and potentially lethal disease. One compelling possibility
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is that genetic factors help drive the mechanisms un-
derlying PCa aggressiveness.
A key pathological measure of aggressiveness is the
Gleason score (Gleason 1992) assigned to a prostate
tumor. The Gleason score reflects the patterns of tissue
architecture observed by a pathologist in two prostate
biopsy or surgery samples. Each pattern is given a
whole-number score between 1 and 5, so the total Glea-
son-score range is 2–10. For tissue with heterogeneous
scores, the maximum two scores are summed to obtain
the total score. Low Gleason scores (i.e., 2–4) indicate
that the tumor cells are well differentiated and are or-
ganized into glandular structures. In contrast, higher
scores (i.e., 8–10) signify less differentiation of the tu-
mor cells: they appear solid and dissipate together. Poor
differentiation and, hence, a high Gleason score, is a
strong prospective gauge of which tumors will penetrate
the prostate capsule, invade the seminal vesicles, and
spread to the lymph nodes. Therefore, genes linked to
Gleason score and, thus, tissue architecture could serve
as molecular markers of PCa aggressiveness. In addi-
tion, such genes may increase our knowledge about the
biological mechanisms underlying the progression of
PCa from latent to invasive disease.
Previous work searching for genetic markers of PCa
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aggressiveness has included loss-of-heterozygosity
(LOH) and candidate-gene approaches (Ware 1994;
Nupponen and Visakorpi 1999). Genomic regions that
have been shown to contain LOH and thus, possibly,
tumor-suppressor genes for more-aggressive PCa in-
clude those on chromosomes 5, 7, 10, and 16 (Taka-
hashi et al. 1994; Oakahashi 1995; Cunningham et al.
1996; Komiya et al. 1996; Elo et al. 1997; Elo et al.
1999). Other work has detected associations between
PCa aggressiveness and variants in numerous candidate
genes, including CYP3A4 (Rebbeck et al. 1998; Paris
et al. 1999), PTEN (McMenamin et al. 1999), the an-
drogen receptor (Giovannucci et al. 1997), and the vi-
tamin D receptor (Ingles et al. 1997). In contrast with
these studies of tumor aggressiveness, linkage analyses
have focused on the detection of regions containing sus-
ceptibility genes—that is, those genes implicated in the
development of PCa. Several regions that have been
identified by linkage analysis may contain genes for PCa
development at chromosomal locations 1q24-25 (HPC1
[MIM 601518]) (Smith et al. 1996), 1q42.2-43 (HPC2
[MIM 602759]) (Berthon et al. 1998), 1p36 (CAPB
[MIM 603688]) (Gibbs et al. 1999), and Xq27-28
(HPCX [MIM 300147]) (Xu et al. 1998). We have re-
cently undertaken a sib-pair genomewide linkage anal-
ysis that detected another PCa-susceptibility locus at
chromosome 16q (Suarez et al. 2000), a region showing
high levels of LOH (Carter et al. 1990a; Elo et al. 1997;
Latil et al. 1997; Elo et al. 1999; Paris et al., in press).
To our knowledge, however, no genomewide scan
has been done to search for PCa-aggressiveness genes.
Therefore, in the present paper, we give results from
a linkage analysis of markers located throughout the
genome, to determine whether they are inherited
along with a predisposition to more-aggressive PCa,
as indicated by Gleason score.
Material and Methods
Subjects
Probands were recruited into this study from urology
practices in St. Louis, Missouri, and Cleveland, Ohio,
as well as from general referrals to the study. The pro-
bands’ self-reported family history of PCa was used as
a guide for recruitment of their affected brothers. In the
present analysis, a total of 513 men from concordant
sibships (i.e., two or more brothers with PCa) in which
at least two brothers had information available on their
Gleason scores were recruited into the study and were
genotyped. A total of 189 families had two affected
brothers, 41 families had three affected brothers, two
families had four affected brothers, and one family had
two pairs of affected brothers who were cousins (for the
equivalent of 326 sib pairs). In addition to 48 new sub-
jects, this sample includes the 465 men who were used
in our recent genomewide scan of susceptibility genes
and who had complete Gleason-score information. The
median age at diagnosis among these men was 65 years
(range 42–91 years). Further details about the original
subjects are given in our previous report (Suarez et al.
2000).
We use Gleason score as a measure of tumor aggres-
siveness, since, as noted above, it is generally considered
to be a strong predictor of survival with PCa (Gleason
1992). Our collaborating pathologists ascribed Gleason
scores to biopsy specimens and, when such specimens
existed, to radical-prostatectomy specimens. For the pre-
sent analyses, we used the Gleason score from the pros-
tatectomy specimen whenever available (78% of all sam-
ples). If it was not available, we used the Gleason score
from the biopsy specimen. The institutional review
boards of Washington University and University Hos-
pitals of Cleveland approved this study, and all subjects
gave informed consent to take part in the project.
Genotyping
DNA was extracted from the study subject’s blood,
by use of standard methods, and was sent to the Center
for Medical Genetics, Marshfield Medical Research
Foundation for genotyping. Samples were typed using
the Marshfield Screening Set 9 (Yuan et al. 1997). With
use of this screening set, 364 autosomal simple-tandem-
repeat polymorphisms, which are spaced at ∼9-cM in-
tervals across the genome (sex-equal maps) and which
have an average heterozygosity of 77% (Broman et al.
1998), were genotyped. We used these markers to con-
firm reported relationships among the sib pairs, using
RELTEST (S.A.G.E. 2000). Resulting exclusions in the
original data are given elsewhere (Suarez et al. 2000).
In the new samples with complete Gleason-score infor-
mation, we detected one pair of monozygotic twins,
which was excluded from our linkage analysis.
Statistical Analysis
For our statistical analysis, we used a multipoint gen-
eralized Haseman-Elston (HE) linkage test (Elston et al.
2000; S.A.G.E. 2000). In particular, we used linear re-
gression in which the dependent variable—the mean-
corrected cross product (i.e., of Gleason scores) between
brothers—is regressed on the estimated proportion of
alleles at a particular marker that are shared among
brothers identical by descent (IBD), which is denoted as
for sib pair j. The form of the model is as follows:pj
ˆE(x  m)(x  m) = a bp (1)1j 2j j ,
where is the Gleason score for individual i in sib pairxij
j and where m is the population mean of all Gleason
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scores. Since Gleason scores only exist for menwith PCa,
we estimated m from the mean Gleason score in our
sample. The expected value of the dependent variable is
equal to the sibling covariance. In the presence of link-
age, sib pairs that share the region—that is, those sib
pairs with high values—are expected to have highlypj
correlated Gleason scores, which imply high sib covar-
iance. In contrast, sib pairs that do not share the re-
gion—that is, those sib pairs with low values—arepj
expected to have less-correlated Gleason scores and low
sib covariance. The regression coefficient b can be writ-
ten as follows:
2b = (1 2v)j , (2)g
where v is the recombination fraction and where 2jg
equals the total genetic variance (Elston et al. 2000).
From (2) we see that, in the presence of tight linkage
(i.e., ), b estimates the genetic variance. Thus, val-v  0
ues of b that are statistically significantly 10 suggest
linkage. The intercept a equals the residual sibling co-
variance. S.A.G.E. (2000) uses a generalized least-
squares approach to fit model (1), estimating a covari-
ance matrix that accounts for the correlation among the
residuals.
We also reanalyzed the data by use of the original HE
approach, which regresses the squared difference of
brothers’ Gleason scores on the estimated proportion of
alleles shared IBD (Haseman and Elston 1972; S.A.G.E.
2000). This approach has been widely used in the past,
and, although it is generally less powerful than the new
HE approach, there are situations where it is more pow-
erful than the new HE method (Palmer et al. 2000).
Because of the pathological criteria used in the as-
signment of Gleason scores, unit increases in scores
might not represent equidistant changes in cellular dif-
ferentiation. For example, the increase in Gleason score
from 5 to 6 likely represents a smaller change in differ-
entiation than does an increase from 6 to 7. This is
because the two values resulting in a Gleason score of
7 are usually 3 and 4, and a value of 4 is given only if
there is relatively poor tumor differentiation. Instead of
the ordinal ranking of Gleason scores used here, one
could instead combine scores into the following four
groups, to indicate similar levels of differentiation: (a)
2–4 (well differentiated); (b) 5 and 6 (moderately dif-
ferentiated); (c) 7 (less moderately differentiated); and
(d) 8–10 (poorly differentiated) (Sakr andGrignon 1997;
Stanford et al. 1999). Therefore, we repeated our anal-
yses by combining Gleason scores in this manner, treat-
ing the midpoints of the categories (i.e., 3, 5.5, 7, and
9) as a continuous variable.
For sibships with more than two brothers, we assumed
that all pairs were independent, since estimates of arepj
pairwise independent under the null hypothesis of no
linkage (Hodge 1984). Allele frequencies were calculated
by random selection of one individual from each family.
Results
The median Gleason score among the men in the present
study was 6 (range 2–10). The frequency distribution of
Gleason scores was as follows: Gleason 2 (1%), Gleason
3 (9%), Gleason 4 (7%), Gleason 5 (26%), Gleason 6
(29%), Gleason 7 (20%), Gleason 8 (4%), Gleason 9
(3%), and Gleason 10 (.2%).
Figure 1 presents the multipoint linkage results from
the new and original HE approaches across all chro-
mosomes (except the X and Y chromosomes). The ver-
tical axis of each chromosome’s plot gives the log(P
value) from the t test of the departure of b from zero,
with 324 df (number of affected sib pairs [326] minus
the number of parameters estimated [2—that is, a and
b]) (S.A.G.E. 2000). The dotted horizontal lines indicate
where (log[.001]=3). With use of the newP ! .001
HE approach, we found evidence ( ) for linkageP ! .001
with Gleason score in three regions on chromosomes
5q, 7q, and 19q. On chromosome 5q, we observed a
relatively broad region (∼26 cM in length) within which
was maintained and a peak ( ) ap-P ! .001 P = .0002
proximately halfway between markers D5S1480
(5q31.3) and D5S820 (5q33.3). For chromosome 7q,
for an ∼8-cM region, with a peak ( )P ! .001 P = .0007
∼2 cM centromeric to D7S1804 (7q32.3). On chro-
mosome 19q, was observed across ∼5 cM,P ! .001
with a peak ( ) at D19S433 (19q12). In ad-P = .0004
dition to these three regions, chromosomes 10 and 18
exhibited intriguing, albeit statistically weaker, peaks at
D10S1248 ( ) and 2 cM centromeric toP = .0012
D18S976 ( ).P = .0024
The original HE approach indicated potential regions
of linkage similar to those seen with the new HE ap-
proach, although generally with statistically weaker re-
sults (fig. 1, broken lines). In particular, for the three
chromosomal regions demonstrating linkage with P !
, the original HE approach gave the following peak.001
P values: chromosome 5q, ; chromosome 7q,P = .0053
; and chromosome 19q, . This resultP = .0076 P = .0088
is not surprising, in light of the increased power that is
potentially available with use of the new HE approach;
this increased power is especially apparent when the
residual correlation is limited (Elston et al. 2000; Palmer
et al. 2000). With use of the original HE approach,
chromosomes 1p and 9q also demonstrated slight link-
age to Gleason score ( ), with peaks betweenP ! .01
D1S1622 and D1S3721 ( ) and at D9S930P = .003
( ).P = .008
Table 1 gives additional details for the Gleason-score
linkage regions on chromosomes 5q, 7q, and 19q. In
particular, for markers within and bordering these
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Figure 1 Results from a genomewide scan of PCa-aggressiveness genes; Gleason score was used as a quantitative trait. Unbroken lines
denote results from the new HE analysis; broken lines denote results from the original HE analysis. Tick marks across horizontal axes indicate
marker locations (in cM) (as specified on the Center for Human Genetics, Marshfield Medical Research Foundation Web site). P values are
from a t test of the HE regression coefficient, with 324 df (number of affected sib pairs [326] minus the number of parameters [2]). Dotted
horizontal lines indicate where (log[P] = 3); thus, for peaks above these lines, .P = .001 P ! .001
regions, intermarker spacing, regression coefficients
from the new HE analysis (plus their standard errors),
and corresponding P values are presented. The regres-
sion coefficients indicate that, in each region, the genetic
variance accounted for by the linkage is slightly greater
than one Gleason-score unit. Furthermore, low P values
extend across relatively broad regions on these chro-
mosomes, providing additional support for the presence
of genes that influence the aggressiveness of PCa (Ter-
williger et al. 1997).
When the four groups of Gleason scores reflecting
tumor differentiation were used, the minimum (new)
HE P values indicated slightly more support for linkage
on chromosome 5q31.3-33.3 but somewhat less evi-
dence for linkage on chromosomes 7q32.3 and 19q12.
In particular, for chromosome 5q, the strongest signal
now gave , with the peak shifted 4 cM telo-P = .00008
meric to the original peak. For chromosome 7q, P =
(shifted 2 cM centromeric to the original peak)..0048
For chromosome 19q, peak (same location).P = .013
The larger P values for chromosomes 7q and 19q are
not necessarily unexpected, because combining scores
reduces variation crucial to the power of our linkage
analysis. Even with this recoding of the Gleason scores,
our results continue to suggest linkage to three regions
that might contain PCa-aggressiveness genes. Use of dif-
ferent allele frequencies (e.g., equal across all markers)
did not materially alter our results (not shown).
Discussion
The results of the present study give evidence (P !
) that loci on chromosomes 5q31.3-33.3, 7q32.3,.001
and 19q12 might contain genes linked to Gleason score,
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Table 1
Multipoint Results from the New HE Analysis, for Regions
on Chromosomes 5q, 7q, and 19q That Show Linkage
with Gleason Score (i.e., with Peak ).P ! .001
Chromosome
and Markera
Intermarker
Distancesb
(cM) bc
Standard
Error of b Pd
5q:
D5S816 8.16 1.11 .40 .0025
D5S1480 12.28 1.32 .39 .0004
D5S820 12.36 1.37 .41 .0004
D5S1471 1.06 .40 .0046
7q:
D7S3061 8.54 1.12 .40 .0026
D7S1804 12.95 1.21 .38 .0008
D7S1824 .80 .39 .0190
19q:
D19S714 9.60 .26 .44 .2781
D19S433 6.81 1.37 .41 .0004
D19S245 9.39 1.14 .41 .0029
D19S178 .94 .39 .0085
a All markers for which or that border the peaksP ! .01
are shown and are listed centromeric to telomeric from top
to bottom.
b Spacing between contiguous markers in genome scan.
Distances shown are between the corresponding marker and
the marker listed immediately below.
c Regression coefficient from HE model (1).
d From a t test with 324 df (number of affected sib pairs
[326] minus number of parameters [2]).
which is a measure of PCa aggressiveness. Recent LOH
and candidate-gene work lends some additional support
to the possibility that PCa-aggressiveness genes reside
within or near these candidate regions. An association
between LOH and tumor-node-metastasis stage has been
detected on the border of the chromosome 5q candidate
region (Cunningham et al. 1996). The candidate gene
a-catenin is also located near this region. This gene is
part of the E-cadherin pathway and has been associated
with PCa aggressiveness in numerous studies (Ewing et
al. 1995; Richmond et al. 1997; Umbas et al. 1997;
Morita et al. 1999). LOH in PCa has also been reported
in a region (chromosome 7q31.1) near the candidate
locus that we have detected on chromosome 7q (Zenk-
lusen et al. 1994; Latil et al. 1995; Cunningham et al.
1996). Recent work has also found associations between
LOH and Gleason score on chromosome 7 (Takahashi
et al. 1994; Oakahashi 1995). To our knowledge, there
has been no LOH or candidate-gene work near the link-
age region on chromosome 19.
In addition to primary linkage on chromosomes 5q,
7q, and 19q, we detected weaker ( ) sig-.001 ! P ! .01
nals on chromosomes 1p, 9q, 10q, and 18p. The chro-
mosome 1p region was also linked to PCa susceptibility
in our earlier work (Suarez et al. 2000) among those
with a positive history of breast cancer, and it is in close
proximity to the CAPB locus (Gibbs et al. 1999). If
there is a single gene driving all of these results, CAPB
may also contribute to PCa aggressiveness. For chro-
mosomes 9q, 10q, and 18p, the peak regions are rela-
tively narrow, primarily reflecting linkage only between
the peak markers and Gleason score (fig. 1).
Although none of the results reported in the present
study fulfill the alpha-level criterion for “significant”
linkage (Lander and Kruglyak 1995), the magnitude of
the results may simply reflect sample-size issues in our
sib-pair study as well as the potential for numerous
genetic and environmental factors interacting in the
multistep progression of PCa from latent to aggressive
disease (Witte et al. 1996).
This multistep process—whereby numerous malig-
nant events are required for a normal cell to trans-
form into a malignant cancer cell (Carter et al.
1990b)—provides the biological rationale for why a
gene might be linked to PCa aggressiveness but not
to PCa development. The multiple steps appear to be
driven by different regulating factors that distinguish
which cancers progress to advanced, lethal disease
(Isaacs et al. 1995; Hayward et al. 1998). More spe-
cifically, some factors may initiate the development
of PCa, whereas others may affect progression from
relatively indolent to invasive disease. In the present
study, we have focused on genetic loci that may reg-
ulate one of the latter steps in PCa: progression to
aggressive disease. More specifically, since Gleason
score reflects the potential progression of PCa to met-
astatic and lethal disease, the regions detected in this
report could harbor tumor-aggressiveness genes. In
contrast, previous linkage analyses of PCa have
searched for chromosomal regions that may contain
genes that regulate an earlier step in the process: in-
itiation of disease. For example, we have previously
detected a region on chromosome 16q23 that may
harbor a PCa-susceptibility gene (Suarez et al. 2000).
Since the steps for initiation and progression may be
unique, it is not surprising that mostly different loci
were detected in our present and previous reports.
While the discovery of susceptibility genes will be
valuable for screening purposes, aggressiveness genes
will provide important information about the most-
appropriate treatment among men in whom PCa has
already been diagnosed. Since most of the men (78%)
we studied had radical prostatectomies, any aggres-
siveness genes within the loci reported here would be
primarily relevant to men with localized PCa diag-
nosed at a younger age (i.e., those men amenable to
having a prostatectomy). Nevertheless, such patients
with PCa constitute a large proportion of men with
the disease who need important information about
the most adequate course of treatment.
A benefit of most of our subjects having undergone
prostatectomies is that the resulting specimens pro-
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vide the most accurate measure of Gleason score. In
contrast, a Gleason score from a needle-biopsy spec-
imen may underestimate the true score. Differential
misclassification of Gleason scores between sib-
lings—arising from their having different treatments
and, thus, different specimens—will, on average, de-
crease the magnitude and statistical significance of the
HE regression coefficients (Ott 1999). To increase the
coefficient’s magnitude and statistical significance,
the degree of Gleason-score misclassification would
have to be related to the brothers’ IBD sharing at the
corresponding marker allele. We have investigated the
impact of misclassification by statistically adjusting
our linkage analysis for whether sibling pairs were
concordant or discordant for PCa treatment (66% of
the pairs were concordant). In particular, in a sub-
sequent linkage analysis, we have used the conven-
tional adjustment approach of inclusion of a covar-
ia te ind ica t ing treatment concordance (or
discordance) between pairs of siblings. This adjust-
ment left our results fundamentally unchanged, and
we observed no linkage between PCa treatment and
IBD sharing of marker alleles at the putative aggres-
siveness loci. Therefore, any misclassification result-
ing from different types of specimens used in the mea-
surement of Gleason score do not appear to have
affected our findings. Furthermore, any misclassifi-
cation would lead to our results underestimating the
actual linkage. Another potential source of misclas-
sification is the fact that a number of different path-
ologists assigned Gleason scores to the specimens.
Our past experience reviewing thousands of cases of
prostate cancer indicates that the scores are repro-
ducible 70% of the time and that they otherwise dis-
agree by no more than one unit. More importantly,
it is inconceivable that misclassification by different
pathologists would be associated with the brothers’
IBD sharing of marker alleles at the aggressiveness
loci. Therefore, any misclassification of the brothers’
Gleason scores arising from different pathologists
would, at most, lead to a limited underestimation of
the true linkage.
In light of the expansion of prostate-specific–antigen
(PSA) screening during part of this project’s recruitment
period (i.e., in the early to mid-1990s), the potential
impact of this diagnostic tool on our results merits con-
sideration. Our primary concern is that, within brother
pairs, earlier detection resulting from PSA screening
could result in one brother having a Gleason score that
is lower than that which would have been observed
prior to the widespread use of PSA tests. Therefore, any
bias resulting from PSA screening will reflect whether
the brothers’ diagnoses were made within concordant
or discordant PSA-screening eras (i.e., pre- and post-
PSA eras) and whether PSA era is linked to the brothers’
IBD sharing of alleles. We investigated this possibility
by undertaking an adjusted linkage analysis that incor-
porated a covariate indicating whether they both had
been given a diagnosis in the same PSA era, using 1994
as a cutoff point for when PSA was fully established as
a screening tool (63% were concordant for PSA-screen-
ing era). We observed no notable differences in the link-
age peaks and found that PSA-screening era is not linked
to IBD sharing of alleles at these aggressiveness loci.
(Using 1992 as a cutoff point for establishment of PSA
screening gave similar results.) This indicates that the
introduction of PSA testing does not appear to have had
any impact on our linkage results.
In summary, our novel genomewide scan of Gleason
score has detected loci on chromosomes 5q31.3-33.3,
7q32.3, and 19q12 that might harbor PCa-aggressive-
ness genes. Detection of such genes may provide im-
portant insights into the underlying mechanism driving
the progression of PCa from latent to invasive disease.
Moreover, knowledge about aggressiveness genes could
help guide treatment plans among men with diagnosed
PCa.
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